The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Bisphosphonate-associated adverse events
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marx, R. E. (2003) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/s0278-2391(03)00720-1 · Cited by 3,036
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Locke, G., Talley, N., Fett, S., Zinsmeister, A., & Melton, L. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70025-8 · Cited by 2,095
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003
Khosla, S., Burr, D., Cauley, J., Dempster, D. W., Ebeling, P. R., Felsenberg, D., Gagel, R. F., Gilsanz, V., Guise, T., Koka, S., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0707onj · Cited by 1,650
Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy
Odvina, C. V., Zerwekh, J. E., Rao, D. S., Maalouf, N., Gottschalk, F. A., & Pak, C. Y. C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0952 · Cited by 1,432
Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S.-B., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,252
Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors
Bamias, A., Kastritis, E., Bamia, C., Moulopoulos, L. A., Melakopoulos, I., Bozas, G., Koutsoukou, V., Gika, D., Anagnostopoulos, A., Papadimitriou, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8670 · Cited by 1,149
Hillner, B. E., Ingle, J. N., Chlebowski, R. T., Gralow, J., Yee, G. C., Janjan, N. A., Cauley, J. A., Blumenstein, B. A., Albain, K. S., Lipton, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.017 · Cited by 970
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M. A., Coleman, R. E., Reitsma, D. J., et al. (2003) · Cancer · doi:10.1002/cncr.11701 · Cited by 873
(2007) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2006.11.003 · Cited by 837
Esophagitis Associated with the Use of Alendronate
de Groen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M. J., Pinkas, H., & Wang, K. K. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351403 · Cited by 764
Chang, B. S., & Lowenstein, D. H. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022308 · Cited by 731
Marx, R. E., Cillo, J. E., & Ulloa, J. J. (2007) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2007.08.003 · Cited by 720
Molecular Mechanisms of Action of Bisphosphonates: Current Status
Roelofs, A. J., Thompson, K., Gordon, S., & Rogers, M. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0843 · Cited by 568
Khosla, S. (2008) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2008.01.054 · Cited by 564
Low-Energy Femoral Shaft Fractures Associated With Alendronate Use
Neviaser, A. S., Lane, J. M., Lenart, B. A., Edobor-Osula, F., & Lorich, D. G. (2008) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0b013e318172841c · Cited by 526
Subtrochanteric insufficiency fractures in patients on alendronate therapy: A CAUTION
Goh, S.-K., Yang, K. Y., Koh, J. S. B., Wong, M. K., Chua, S. Y., Chua, D. T. C., & Howe, T. S. (2007) · The Journal of Bone and Joint Surgery. British volume · doi:10.1302/0301-620x.89b3.18146 · Cited by 513
Bisphosphonates in Bone Disease: From the Laboratory to the Patient
Fleisch, H. A. (1995) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 472
Wysowski, D. K., & Swartz, L. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1363 · Cited by 471
Kwek, E. B. K., Goh, S. K., Koh, J. S. B., Png, M. A., & Howe, T. S. (2008) · Injury · doi:10.1016/j.injury.2007.08.036 · Cited by 445
Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy
Weinstein, R. S., Roberson, P. K., & Manolagas, S. C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0802633 · Cited by 391
Renal Failure with the Use of Zoledronic Acid
(2003) · New England Journal of Medicine · doi:10.1056/nejm200310233491721 · Cited by 367
Perazella, M. A., & Markowitz, G. S. (2008) · Kidney International · doi:10.1038/ki.2008.356 · Cited by 363
The acute-phase response after bisphosphonate administration
Adami, S., Bhalla, A. K., Dorizzi, R., Montesanti, F., Rosini, S., Salvagno, G., & Lo Cascio, V. (1987) · Calcified Tissue International · doi:10.1007/bf02556671 · Cited by 357
Ruggiero, S. L., Gralow, J. R., Marx, R. E., Hoff, A. O., Schubert, M. M., Huryn, J. M., Toth, B., Damato, K., & Valero, V. (2006) · Journal of Oncology Practice · doi:10.1200/jop.2.1.7 · Cited by 355
Miller, P. D., Mcclung, M. R., Macovei, L., Stakkestad, J. A., Luckey, M., Bonvoisin, B., Reginster, J.-Y., Recker, R. R., Hughes, C., Lewiecki, E. M., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050313 · Cited by 333
Miller, P. D., Roux, C., Boonen, S., Barton, I. P., Dunlap, L. E., & Burgio, D. E. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050817 · Cited by 318
Management of the adverse effects associated with intravenous bisphosphonates
Tanvetyanon, T., & Stiff, P. J. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj105 · Cited by 301
Pazianas, M., Miller, P., Blumentals, W. A., Bernal, M., & Kothawala, P. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.08.008 · Cited by 298
Severely Suppressed Bone Turnover and Atypical Skeletal Fragility
Visekruna, M., Wilson, D., & McKiernan, F. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2803 · Cited by 270
Hewitt, R. E., Lissina, A., Green, A. E., Slay, E. S., Price, D. A., & Sewell, A. K. (2004) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2005.02665.x · Cited by 241
Alendronate and Atrial Fibrillation
Cummings, S. R., Schwartz, A. V., & Black, D. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmc076132 · Cited by 230
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis
Rizzoli, R., Burlet, N., Cahall, D., Delmas, P. D., Eriksen, E. F., Felsenberg, D., Grbic, J., Jontell, M., Landesberg, R., Laslop, A., et al. (2008) · Bone · doi:10.1016/j.bone.2008.01.003 · Cited by 223
Upper Gastrointestinal Tract Safety Profile of Alendronate: The Fracture Intervention Trial
Bauer, D. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.517 · Cited by 215
Use of Alendronate and Risk of Incident Atrial Fibrillation in Women
Heckbert, S. R., Li, G., Cummings, S. R., Smith, N. L., & Psaty, B. M. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.8.826 · Cited by 199
Reports of Esophageal Cancer with Oral Bisphosphonate Use
Wysowski, D. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0808738 · Cited by 198
Relationship between age, renal function and bone mineral density in the US population
Klawansky, S., Komaroff, E., Cavanaugh, P. F., Mitchell, D. Y., Gordon, M. J., Connelly, J. E., & Ross, S. D. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1435-y · Cited by 196
RENAL FAILURE ASSOCIATED WITH INTRAVENOUS DIPHOSPHONATES
Bounameaux, H., Schifferli, J., Montani, J.-P., Jung, A., & Chatelanat, F. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91465-4 · Cited by 193
Harris, S. T. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.6.1399 · Cited by 182
Sørensen, H. T., Christensen, S., Mehnert, F., Pedersen, L., Chapurlat, R. D., Cummings, S. R., & Baron, J. A. (2008) · BMJ · doi:10.1136/bmj.39507.551644.be · Cited by 178
Avascular necrosis of the jaws: risk factors in metastatic cancer patients
Tarassoff, P., & Csermak, K. (2003) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2003.09.001 · Cited by 175
Edwards, B. J.-A., Gounder, M. M., McKoy, J. M., Boyd, I. W., Farrugia, M., Migliorati, C. A., Marx, R., Ruggiero, S. L., Dimopoulos, M. A., Raisch, D. W., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70305-x · Cited by 150
Imaging Findings of Bisphosphonate-Associated Osteonecrosis of the Jaws
Phal, P. M., Myall, R. W. T., Assael, L. A., & Weissman, J. L. (2007) · American Journal of Neuroradiology · doi:10.3174/ajnr.a0518 · Cited by 149
Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?
Cryer, B., & Bauer, D. C. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.10.1031 · Cited by 148
Alendronate‐related oral mucosa ulcerations
González‐Moles, M. Á., & Sebastián, J. V. B. (2000) · Journal of Oral Pathology and Medicine · doi:10.1034/j.1600-0714.2000.291006.x · Cited by 111
Bisphosphonate-Induced Hypocalcemia: Report of 3 Cases and Review of Literature
Maalouf, N. M., Heller, H. J., Odvina, C. V., Kim, P. J., & Sakhaee, K. (2006) · Endocrine Practice · doi:10.4158/ep.12.1.48 · Cited by 105
Koo, S., Kucher, N., Fanikos, J., & Goldhaber, S. Z. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.3.346-b · Cited by 103
Greenspan, S. L., Field-Munves, E., Tonino, R. P., Smith, M. E., Petruschke, R. A., Wang, L., Yates, J., de Papp, A. E., & Palmisano, J. J. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.10.1044 · Cited by 93
Significance and impact of bisphosphonate-induced acute phase responses
Olson, K. B., & Poznak, C. H. V. (2007) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155207080806 · Cited by 87
Yearly zoledronic acid in postmenopausal osteoporosis.
Karam, R., Camm, A. J., & McClung, M. R. (2007) · PubMed · Cited by 87
The Impact of Primary Hyperparathyroidism on the Oral Cavity
Padbury, A. D., Tözüm, T. F., Taba, M., Bumann, E. E., West, B. T., Burney, R. E., Gauger, P. G., Giannobile, W. V., & McCauley, L. K. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2282 · Cited by 81
Musculoskeletal pain in female asylum seekers and hypovitaminosis D 3
de la Jara, G. D. T., Pécoud, A. R., & Favrat, B. (2004) · BMJ · doi:10.1136/bmj.329.7458.156 · Cited by 76
Specific Features Associated with Femoral Shaft Fractures Caused by Low-Energy Trauma
Salminen, S. T., PIHLAJAMÄKI, H. K., Avikainen, V., Kyrö, A., & Böstman, O. M. (1997) · doi:10.1097/00005373-199707000-00027 · Cited by 75
Bock, O., Börst, H., Thomasius, F. E., Degner, C., Stephan-Oelkers, M., Valentine, S. M., & Felsenberg, D. (2007) · PubMed · Cited by 61
Yearly Zoledronic Acid in Postmenopausal Osteoporosis
de Nijs, R. N. J., & Westgeest, A. A. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmc071514 · Cited by 59
Miura, N., Mizuno, N., Aoyama, R., Kitagawa, W., Yamada, H., Nishikawa, K., & Imai, H. (2008) · Clinical and Experimental Nephrology · doi:10.1007/s10157-008-0078-x · Cited by 54
Bobba, R. S., BEATTIE, K. A., Parkinson, B., Kumbhare, D. A., & Adachi, J. D. (2006) · Drug Safety · doi:10.2165/00002018-200629120-00005 · Cited by 48
Bergner, R., Diel, I., Henrich, D. M., Hoffmann, M. F., & Uppenkamp, M. J. (2006) · Oncology Research and Treatment · doi:10.1159/000096056 · Cited by 46
Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws
THIERS, B. H. (2007) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70544-6 · Cited by 43
Liver Damage Due to Alendronate
Halabe, A., LIFSCHITZ, B. M., & Azuri, J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008033430512 · Cited by 40
Bisphosphonate-associated Scleritis: A Case Report and Review
Leung, S., Ashar, B. H., & Miller, R. G. (2005) · Southern Medical Journal · doi:10.1097/01.smj.0000152753.80490.9f · Cited by 38
Unilateral anterior uveitis complicating zoledronic acid therapy in breast cancer
Saghir, N. S. E., Otrock, Z. K., & Bleik, J. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-156 · Cited by 38
Eisman, J. A., Rizzoli, R., Román-Ivorra, J., Lipschitz, S., Verbruggen, N., Gaines, K. A., & Melton, M. E. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003548 · Cited by 38
Bilateral acute anterior uveitis after alendronate
Malik, A. R. (2002) · British Journal of Ophthalmology · doi:10.1136/bjo.86.12.1443 · Cited by 37
A case report: zoledronic acid-induced anterior uveitis
Kılıçkap, S., Özdamar, Y., Altundag, M. K., & Dızdar, Ö. (2007) · Medical Oncology · doi:10.1007/s12032-007-9006-2 · Cited by 33
Srivastava, T., Haney, C. J., & Alon, U. S. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081016 · Cited by 32
Use of Alendronate and Risk of Incident Atrial Fibrillation in Women
Heckbert, S. R., Li, G., Cummings, S. R., Smith, N. L., & Psaty, B. M. (2008) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000325913.95041.9a · Cited by 26
From the laboratory to the patient
Gwynne, P. J. (2003) · Physics World · doi:10.1088/2058-7058/16/8/37 · Cited by 25
Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases.
Anastasilakis, A. D., Goulis, D. G., Kita, M. D., & Avramidis, A. (2007) · PubMed · Cited by 22
Clarke, B. L. (2006) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70408-6 · Cited by 15
Cytokines in Primary Hyperparathyroidism
Nakchbandi, I. A., Grey, A. B., MASIUKIEWICZ, U. S., Mitnick, M., & Insogna, K. L. (2001) · Elsevier eBooks · doi:10.1016/b978-012098651-4/50027-4 · Cited by 4
Cited by
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y.-T., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 261
Metadata
- Authors
- Papapetrou, P. D.
- Venue
- Hormones
- Published
- 2009-04
- Volume
- 8
- Issue
- 2
- Pages
- 96-110
- ISSN
- 1109-3099 (ISSN-L)
- 2520-8721
- OpenAlex
- W2101516738
- Cited by
- 312
- References
- 74
- FWCI
- 8.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.